Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1;79(3):307-309.
doi: 10.1001/jamaneurol.2021.5109.

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

Marton König  1 , Hilde Marie Torgauten  2 , The Trung Tran  3 , Trygve Holmøy  4 , John Torgils Vaage  3 , Fridtjof Lund-Johansen  3 , Gro Owren Nygaard  1
Affiliations

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

Marton König et al. JAMA Neurol. .

Abstract

This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune response to COVID-19 vaccination.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr König reported receiving speaker honoraria from Novartis, Biogen, and AstraZeneca outside the submitted work. Dr Holmøy reported receiving speaker honoraria from Merck, Biogen, Genzyme, Sanofi, Novartis, Roche, and Bristol Myers Squibb during the conduct of the study. No other disclosures were reported.

Figures

Figure.
Figure.. Development of Anti–SARS-CoV-2 Spike Receptor-Binding Domain (RBD) IgG Levels in Patients With Multiple Sclerosis Who Were Treated With Anti-CD20 or Fingolimod and Underwent Revaccination
Reduced immunity was assumed in individuals with IgG levels < 70 arbitrary units (AU; red horizontal line) corresponding to a lower level than found in 99% of healthy vaccinated individuals. S2 indicates antibody sample after second vaccine dose; S3, antibody sample after third vaccine dose.
See this image and copyright information in PMC

Comment in

References

    1. Achiron A, Mandel M, Dreyer-Alster S, et al. . Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012835. doi:10.1177/17562864211012835 - DOI - PMC - PubMed
    1. König M, Lorentzen AR, Torgauten HM, et al. . Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. J Neurol Neurosurg Psychiatry. 2021;jnnp-2021-327612. doi:10.1136/jnnp-2021-327612 - DOI - PMC - PubMed
    1. Brill L, Rechtman A, Zveik O, et al. . Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol. Published online September 23, 2021. doi:10.1001/jamaneurol.2021.3599 - DOI - PMC - PubMed
    1. Holter JC, Pischke SE, de Boer E, et al. . Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci U S A. 2020;117(40):25018-25025. doi:10.1073/pnas.2010540117 - DOI - PMC - PubMed
    1. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. . Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423-4428. doi:10.1016/j.vaccine.2021.05.063 - DOI - PMC - PubMed